我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
10
5 进行中
药物批准
4
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
5
50.0%
已完成
EMA
European Medicines Agency
1
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
3
- Orphalan has acquired Orphelia Pharma, a company specializing in rare and severe pediatric diseases in neurology and oncology, strengthening its position as a European leader in rare diseases. - The acquisition expands Orphalan's capabilities in rare neurological and oncological pediatric diseases while improving access to medicines for children and adults with rare conditions. - Orphelia Pharma brings one authorized medicine in the European Union (Kigabeq®) and a second under regulatory review (Kizfizo®) to the combined platform. - The strategic transaction creates a unique platform combining scientific excellence, agility, and global commercialization capabilities to accelerate innovation in orphan diseases.
